In this study we have examined the effects on colon cancer cells of two scenarios in which canonical TR1 activity (i.e. the ability to reduce Trx) has been mitigated either by siRNA treatment or mutation of the C-terminal Sec and Cys residues. The gene discussed is TXNRD1; the disease is colonic neoplasm.